Clinical features, treatment and outcomes of dabrafenib-associated uveitis.

BACKGROUND

To explore the clinical characteristics of dabrafenib-associated uveitis and provide a basis for diagnosis and treatment.

METHODS

The database was retrieved to collect reports of dabrafenib-associated uveitis and clinical data were collected for retrospective analysis.

RESULTS

Twenty-six patients were included in the study, with a median age of 56 years (range 30, 75). The onset time of uveitis was 3 months (range 0.75, 96) after administration. The types of uveitis were pan-uveitis (38.5%), anterior uveitis (34.6%), posterior uveitis (15.4%), and intermediate uveitis (3.8%). Fifty percent of the patients were Vogt-Koyanagi-Harada disease-like uveitis. After discontinuation of dabrafenib and treatment with topical and systemic steroids, the symptoms of uveitis improved in all patients.

CONCLUSION

Patients are advised to have regular ophthalmology examinations during the use of dabrafenib. Timely administration of systemic or local corticosteroid treatment can significantly improve the symptoms of patients.